US pharma manufacturer enters Chapter 11 after failed takeover and FDA warnings

Aiming to seek an in-court sale of its business, international pharma company Akorn and its US subsidiaries have entered Chapter 11 following a failed takeover and multiple actions and warnings from the US’s Federal Drug Administration.

Get unlimited access to all Global Restructuring Review content